2017 Cardiovascular Research Day Abstract Book
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
40<br />
The Prognostic Role of Elevated Myeloperoxidase in Patients with Acute Coronary<br />
Syndrome: A Systematic Review and Meta-Analysis<br />
Mohamed Abo-Aly, MD 1 • Andrew kolodziej, MD 1 • Raphael Twerenbold, MD 1 •<br />
Christian Mueller, MD 1 • Ahmed Abdel-Latif, MD, PhD 1<br />
1Division of cardiovascular medicine, Gill heart institution., University of Kentucky<br />
Postdoc<br />
Background:<br />
Many reports have shown the correlation between myeloperoxidase (MPO) and the pathogenesis of<br />
acute coronary syndrome (ACS). However, the prognostic role of MPO for major cardiac events or<br />
mortality in ACS patients has not been well studied. We sought to perform a systematic review and<br />
meta-analysis to examine the prognostic value of inpatient MPO level in patients presenting with<br />
ACS.<br />
Methods:<br />
PubMed and Cochrane databases were searched from 1975 to September <strong>2017</strong> for studies that<br />
investigated the prognostic value of serum MPO in patients with ACS. Studies should have<br />
dichotomized patients into a high MPO and a low MPO group, reported clinical outcomes according<br />
to the same cutoff value of MPO and followed up patients for at least 30 days to be eligible for<br />
enrollment. Data were analyzed using random-effects model to control heterogeneous reporting.<br />
Results:<br />
We retrieved 3896 studies for initial screening which yielded 14 studies including 9268 subjects<br />
with a median follow up of 8.7 ± 21.96 months for the final analysis. High serum MPO level<br />
significantly predicts the future risk of mortality (odds ratio [OR] 2.039; 95% confidence interval<br />
[CI]: 1.405-2.959; P=0.0176) and MACE (OR 1.42; 95% CI: 1.00-1.99; p=0.044). we also observed a<br />
string trend towards higher incidence of recurrent myocardial infarction (MI) in patients with high<br />
MPO level (OR 1.24; 95% CI: 0.99-1.54; p=0.054) in comparison to patients with low serum MPO.<br />
Conclusion:<br />
In this meta-analysis examining the long outcomes in ACS patients, high MPO levels were associated<br />
with worse clinical outcomes. These observations support the use of MPO as a novel clinical<br />
prognostic marker in patients with acute coronary syndrome.<br />
56